These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 15781813

  • 1. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 2. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 22; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 3. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
    Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 5. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J.
    Expert Opin Investig Drugs; 2009 Jul 20; 18(7):985-9. PubMed ID: 19527103
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 20; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 7. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
    Neurology; 2007 Aug 21; 69(8):785-9. PubMed ID: 17709711
    [Abstract] [Full Text] [Related]

  • 8. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5062 Study Group.
    Lancet; 2008 Jun 21; 371(9630):2085-92. PubMed ID: 18572078
    [Abstract] [Full Text] [Related]

  • 9. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 21; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 10. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 28; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 12. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group.
    Neurology; 2005 Sep 13; 65(5):690-5. PubMed ID: 16157900
    [Abstract] [Full Text] [Related]

  • 13. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.
    J Neurol Sci; 2008 Apr 15; 267(1-2):28-35. PubMed ID: 17945260
    [Abstract] [Full Text] [Related]

  • 14. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 15. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 16. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 23; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 17. Blockade of chemokine signaling in patients with multiple sclerosis.
    Zipp F, Hartung HP, Hillert J, Schimrigk S, Trebst C, Stangel M, Infante-Duarte C, Jakobs P, Wolf C, Sandbrink R, Pohl C, Filippi M, CCR1 Antagonist Study Group.
    Neurology; 2006 Nov 28; 67(10):1880-3. PubMed ID: 17130431
    [Abstract] [Full Text] [Related]

  • 18. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
    Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5063 Study Group.
    Mult Scler; 2010 Nov 28; 16(11):1360-6. PubMed ID: 20834039
    [Abstract] [Full Text] [Related]

  • 19. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
    Mult Scler; 2009 Oct 28; 15(10):1183-94. PubMed ID: 19776092
    [Abstract] [Full Text] [Related]

  • 20. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.
    Arch Neurol; 2007 Oct 28; 64(10):1407-15. PubMed ID: 17698695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.